A sensitive laboratory test known as MRD has helped many children who live with leukaemia. It does this by detecting tiny levels of leukaemic cells that remain in bone marrow as treatment progresses. But certain genetic mutations mean that it’s not successful with some children, so this project aims to identify these mutations and develop improved treatment strategies.
Our funding is helping the team identify those genetic mutations that prevent the successful use of MRD testing, which relies on the identification of specific genetic changes in leukaemic cells.
Molecular tracking of treatment response in paediatric AML
Dr Richard Dillon
King's College London
London SE1 9RT
1 April 2016